Literature DB >> 22238384

Orbit-infiltrating mast cells, monocytes, and macrophages produce PDGF isoforms that orchestrate orbital fibroblast activation in Graves' ophthalmopathy.

L van Steensel1, D Paridaens, M van Meurs, P M van Hagen, W A van den Bosch, R W A M Kuijpers, H A Drexhage, H Hooijkaas, W A Dik.   

Abstract

PURPOSE: Platelet-derived growth factors (PDGF) are regulators of fibroblast activity that may be involved in the pathophysiology of Graves' ophthalmopathy (GO). We unraveled the expression and origin of PDGF family members in GO orbital tissue and investigated the effect of PDGF isoforms on IL-6 and hyaluronan production and proliferation by orbital fibroblasts.
METHODS: PDGF-A, PDGF-B, PDGF-C, PDGF-D, PDGF-Rα, and PDGF-Rβ expression was determined by real-time quantitative PCR and PDGF-A and PDGF-B protein expression was determined by Western blot in orbital tissues. Orbital tissues were immunohistochemically stained for PDGF-A and PDGF-B expression, together with stainings for T cells, monocytes, B cells, macrophages, and mast cells. Effects of PDGF-AA, PDGF-AB, and PDGF-BB on orbital fibroblast proliferation and IL-6 and hyaluronan production were examined. Finally, effects of PDGF-BB- and PDGF-AA-neutralizing antibodies on IL-6 and hyaluronan production in GO whole orbital tissue cultures were tested.
RESULTS: GO orbital tissue showed increased PDGF-A and PDGF-B mRNA and protein levels. Increased numbers of PDGF-A- and PDGF-B-positive monocytes, macrophages, and mast cells were present in GO orbital tissue. PDGF-BB stimulated proliferation and hyaluronan and IL-6 production by orbital fibroblasts the most, followed by PDGF-AB and PDGF-AA. Finally, in particular imatinib mesylate and PDGF-BB-neutralizing antibodies reduced IL-6 and hyaluronan production by whole orbital tissue cultures from GO patients.
CONCLUSIONS: In GO, mast cells, monocytes, and macrophages may activate orbital fibroblasts via secretion of especially PDGF-AB and PDGF-BB. Preclinical studies with whole orbital tissue cultures show that blocking PDGF-B chain containing isoforms can be a promising treatment for GO.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22238384     DOI: 10.1210/jc.2011-2697

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  19 in total

Review 1.  Insulin-like Growth Factor-I Receptor and Thyroid-Associated Ophthalmopathy.

Authors:  Terry J Smith; Joseph A M J L Janssen
Journal:  Endocr Rev       Date:  2019-02-01       Impact factor: 19.871

Review 2.  TSH-receptor-expressing fibrocytes and thyroid-associated ophthalmopathy.

Authors:  Terry J Smith
Journal:  Nat Rev Endocrinol       Date:  2015-01-06       Impact factor: 43.330

Review 3.  Graves' orbitopathy: imperfect treatments for a rare disease.

Authors:  Luigi Bartalena
Journal:  Eur Thyroid J       Date:  2013-11-20

Review 4.  Immunohistochemical analysis of human orbital tissue in Graves' orbitopathy.

Authors:  Y P Hai; A C H Lee; L Frommer; T Diana; G J Kahaly
Journal:  J Endocrinol Invest       Date:  2019-09-19       Impact factor: 4.256

Review 5.  Thyroid eye disease: current and potential medical management.

Authors:  Jessica M Pouso-Diz; Jose M Abalo-Lojo; Francisco Gonzalez
Journal:  Int Ophthalmol       Date:  2020-01-09       Impact factor: 2.031

Review 6.  Platelet-derived growth factor: a key factor in the pathogenesis of graves' ophthalmopathy and potential target for treatment.

Authors:  Sita Virakul; Leendert van Steensel; Virgil A S H Dalm; Dion Paridaens; P Martin van Hagen; Willem A Dik
Journal:  Eur Thyroid J       Date:  2014-12-06

7.  Factor Xa and thrombin stimulate proinflammatory and profibrotic mediator production by retinal pigment epithelial cells: a role in vitreoretinal disorders?

Authors:  Jeroen Bastiaans; Jan C van Meurs; Conny van Holten-Neelen; Marja Smits-Te Nijenhuis; Marion J Kolijn-Couwenberg; P Martin van Hagen; Robert W A M Kuijpers; Herbert Hooijkaas; Willem A Dik
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2013-04-20       Impact factor: 3.117

8.  The tyrosine kinase inhibitor dasatinib effectively blocks PDGF-induced orbital fibroblast activation.

Authors:  Sita Virakul; Virgil A S H Dalm; Dion Paridaens; Willem A van den Bosch; Nattiya Hirankarn; P Martin van Hagen; Willem A Dik
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2014-05-30       Impact factor: 3.117

Review 9.  New insights into the pathogenesis and nonsurgical management of Graves orbitopathy.

Authors:  Peter N Taylor; Lei Zhang; George J Kahaly; Marian Ludgate; Richard W J Lee; Ilaria Muller; Daniel G Ezra; Colin M Dayan
Journal:  Nat Rev Endocrinol       Date:  2019-12-30       Impact factor: 43.330

10.  Slit2 Regulates Hyaluronan & Cytokine Synthesis in Fibrocytes: Potential Relevance to Thyroid-Associated Ophthalmopathy.

Authors:  Roshini Fernando; Terry J Smith
Journal:  J Clin Endocrinol Metab       Date:  2021-01-01       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.